The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging
Open accessAbstract
PURPOSE: To retrospectively determine whether relative cerebral blood volume (CBV) measurements can be used to predict clinical outcome in patients with high-grade gliomas (HGGs) and low-grade gliomas (LGGs) and specifically whether patients who have gliomas with a high initial relative CBV have more rapid progression than those who have gliomas with a low relative CBV. MATERIALS AND METHODS: Approval for this retrospective HIPAA-compliant study was obtained from the Institutional Board of Research Associates, with waiver of informed consent. One hundred eighty-nine patients (122 male and 67 female patients; median age, 43 years; range, 4-80 years) were examined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance (MR) imaging and were followed up clinically with MR imaging (median follow-up, 334 days). Log-rank tests were used to evaluate the association between relative CBV and time to progression by using Kaplan-Meier curves. Binary logistic regression was used to determine whether age, sex, and relative CBV were associated with an adverse event (progressive disease or death). RESULTS: Values for the mean relative CBV for patients according to each clinical response were as follows: 1.41 +/- 0.13 (standard deviation) for complete response (n = 4), 2.36 +/- 1.78 for stable disease (n = 41), 4.84 +/- 3.32 for progressive disease (n = 130), and 3.82 +/- 1.93 for death (n = 14). Kaplan-Meier estimates of median time to progression in days indicated that patients with a relative CBV of less than 1.75 had a median time to progression of 3585 days, whereas patients with a relative CBV of more than 1.75 had a time to progression of 265 days. Age and relative CBV were also independent predictors for clinical outcome. CONCLUSION: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can be used to predict median time to progression in patients with gliomas, independent of pathologic findings. Patients who have HGGs and LGGs with a high relative CBV (>1.75) have a significantly more rapid time to progression than do patients who have gliomas with a low relative CBV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Perfusion imaging with NMR contrast agents
Rosen, B. R., Belliveau, J. W., Vevea, J. M., & Brady, T. J. (1990) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910140211 · Cited by 1,151
Law, M., Yang, S., Wang, H., Babb, J. S., Johnson, G., Cha, S., Knopp, E. A., & Zagzag, D. (2003) · PubMed Central · Cited by 1,084
Self-citationGrading of astrocytomas: A simple and reproducible method
Daumas-Duport, C., Scheithauer, B., O'Fallon, J., & Kelly, P. (1988) · Cancer · doi:10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t · Cited by 891
Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications
Burger, P. C., Vogel, F. S., Green, S. B., & Strike, T. A. (1985) · Cancer · doi:10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2 · Cited by 651
Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Law, M., Yang, S., Babb, J. S., Knopp, E. A., Golfinos, J. G., Zagzag, D., & Johnson, G. (2004) · PubMed Central · Cited by 508
Self-citationUpdate on brain tumor imaging: from anatomy to physiology.
Cha, S. (2006) · PubMed · Cited by 447
Limitations of stereotactic biopsy in the initial management of gliomas
Jackson, R. J., Fuller, G. N., Abi-Said, D., Lang, F. F., Gokaslan, Z. L., Shi, W. M., Wildrick, D. M., & Sawaya, R. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.3.193 · Cited by 416
Lev, M. H., Özsunar, Y., Henson, J. W., Rasheed, A. A., Barest, G. D., Harsh, G. R., Fitzek, M. M., Chiocca, E. A., Rabinov, J. D., Csavoy, A. N., et al. (2004) · PubMed Central · Cited by 409
Cited by
Principles, Techniques, and Applications of T2*-based MR Imaging and Its Special Applications
Chavhan, G. B., Babyn, P. S., Thomas, B., Shroff, M. M., & Haacke, E. M. (2009) · RadioGraphics · doi:10.1148/rg.295095034 · Cited by 740
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Current Clinical Brain Tumor Imaging
Villanueva-Meyer, J. E., Mabray, M. C., & Cha, S. (2017) · Neurosurgery · doi:10.1093/neuros/nyx103 · Cited by 453
Kickingereder, P., Burth, S., Wick, A., Götz, M., Eidel, O., Schlemmer, H.-P., Maier-Hein, K. H., Wick, W., Bendszus, M., Radbruch, A., et al. (2016) · Radiology · doi:10.1148/radiol.2016160845 · Cited by 446
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 368
Metadata
- Authors
- Law, M., Young, R. J., Babb, J. S., Peccerelli, N., Chheang, S., Gruber, M. L., Miller, D. C., Golfinos, J. G., Zagzag, D., & Johnson, G.
- Venue
- Radiology
- Published
- 2008-05
- Volume
- 247
- Issue
- 2
- Pages
- 490-498
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2019068225
- Cited by
- 534
- References
- 24
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. https://app.cochat.ai/papers/10.1148/radiol.2472070898
- The paper
- Law, M., Young, R. J., Babb, J. S., Peccerelli, N., Chheang, S., Gruber, M. L., Miller, D. C., Golfinos, J. G., Zagzag, D., & Johnson, G. (2008). Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology. https://doi.org/10.1148/radiol.2472070898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.